» Brazil and Mexico present an attractive opportunity for biosimilar manufacturers.
RESULTS

»
» Interviewed payers confirmed previous negative experiences with non-original biologics in their markets. In Mexico, immunogenic responses were observed in patients that were frequently switched between treatment with MabThera (rituximab) and its copy biologic, Kikuzubam. In Brazil, the first non-innovator interferons produced by Productive Development Partnerships (PDPs) demonstrated lower efficacy 1 .
» At the same time, surveyed physicians report that up to 53% of biologics-eligible public patients with a given tumor type do not currently receive a biologic ( Figure 2 » Procuring and prescribing is by generic name in the public healthcare institutions of Brazil and Mexico. Due to these practices, surveyed physicians and interviewed payers expect that biosimilars for oncology will automatically and inevitably substitute the original brands, particularly in the public sector (Figure 3 
DISCUSSION AND CONCLUSION
» Oncology biosimilars should find fertile terrain in Brazil and Mexico. Automatic substitution in the public sector is highly likely (Figures 3, 4 ).
» Negative experiences with non-innovator copy biologics may hinder greater adoption of biosimilars. However, payers believe that past negative experiences should not impact prescribers' perception of the quality of oncology biosimilars still to come.
» Evidence from comparative clinical trials and key stakeholder support will be crucial to overcome concerns of lower efficacy and safety from biosimilars, particularly for uptake in the private sector that prefers branded agents.
» Cost-effectiveness combined with pharmacovigilance and robust long-term safety data will play a major role in the continuous uptake of biosimilars versus brands, with the latter securing reasonable market share only if priced competitively in the public and private sectors (Figure 4 ).
» Even subcutaneous (SC) versions of the innovator monoclonal antibodies (MAbs)
for oncology may struggle to compete with lower-priced biosimilars with intravenous (IV) delivery. To gain and maintain market share, overall costs of SC branded biologics must be competitive with the overall costs of IV biosimilars, including their expenses in hospital overhead due to IV administration (Figure 4) .
» Upon the launch of biosimilars, there should be an overall reduced burden from oncology biologics to the healthcare systems in Brazil and Mexico.
» Although interchangeability regulations are still under discussion in both markets, indication extrapolation will likely be practiced in the public sector (Figure 4 ).
The Only if my institution forced me to switch to the biosimilar, which is likely.
PAYERS AND ONCOLOGISTS CONSIDER THE COST-EFFECTIVENESS OF THESE CHEAPER ALTERNATIVES
In general, yes, if the patient was in agreement.
No, I would only consider biosimilars for new patients, if at all.
Would you switch some patients already receiving branded biologics to the respective biosimilar?
It's allowed and inevitable in the public sector, but I disagree with it.
It's allowed, and I support it with my country's regulatory approval of the biosmilar
Not aware of regulation/Other
Is pharmacy-level substitution for biologics accepted in your country and do you agree?
FIGURE 4: PAYER INSIGHT ON THE IMPACT OF BIOSIMILARS ON THE ONCOLOGY MARKET
BIOSIMILARS FOR ONCOLOGY
IMPACT
"As happened when generic drugs launched, I strongly believe that manufacturers of branded biologics will need to offer discounts (20 to 25%) to continue providing customers, especially those in private health. In public health, since the biosimilar will be there, the branded drug will have difficulties maintaining that market."
-Medical Auditor at Private HMO "If the amount spent on the IV drug plus infusion costs is lower than the cost of acquisition of the SC presentation, then public institutions in general will likely retain the IV as a treatment option." • Trastuzumab is not covered in the SUS for advanced breast cancer.
• Cetuximab and bevacizumab lack coverage in SP and SUS for metastatic colorectal cancer.
• Rituximab is covered only for certain NHL subtypes in the SUS and in SP.
"The expansion of the covered indications for these oncology MAbs is expected, and this would be one of the benefits of the PDPs project. However, that will only happen if the obtained savings are very advantageous as to allow us to treat more patients with the same financial resources." 
